March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
1 citations
,
November 2016 in “International Journal of Research in Dermatology” The study found no significant link between the symptoms, tissue analysis, and immunofluorescence results in scarring hair loss conditions.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
13 citations
,
August 2017 in “Journal of Cellular Physiology” PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.
October 2025 in “Scholars Journal of Medical Case Reports” Intralesional corticosteroids effectively treat scalp Discoid Lupus and restore hair.
October 2025 in “Clinical Cosmetic and Investigational Dermatology” Targeting specific cell interactions may help treat skin fibrosis.
September 2019 in “Journal of Investigative Dermatology” Innate lymphoid cells type 1 may contribute to alopecia areata.
7 citations
,
May 2021 in “Clinical Case Reports” Alopecic and aseptic nodules of the scalp are rare, treatable, and often resolve with doxycycline or on their own.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
May 2025 in “The Journal of Rheumatology” Purpura fulminans can signal underlying autoimmune disorders, not just infections.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
14 citations
,
August 2004 in “Veterinary Dermatology” The horse had a rare type of hair loss caused by immune cells attacking hair follicles.
101 citations
,
July 2020 in “Dermatologic therapy” COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
23 citations
,
April 1993 in “Gastroenterology” A mother and son both had ulcerative colitis and alopecia, suggesting a genetic link in autoimmune disorders and successful treatment with cyclosporine.
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.
1 citations
,
September 2022 Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
The nail immune system is similar to hair but different from skin, with fewer immune markers.
33 citations
,
September 2007 in “Veterinary dermatology” Topical 0.1% tacrolimus significantly improved ear infections in cats.
December 2022 in “Gastroenterology” A man with Cronkhite-Canada syndrome improved significantly with immunosuppressive therapy.
4 citations
,
February 1996 in “Postgraduate Medical Journal” Finasteride linked to skin inflammation.
49 citations
,
January 2012 in “Dermatology” Severe anti-TNF-α induced scalp eruptions often need stopping the drug and using systemic therapy to avoid scarring.
September 2025 in “Clinical and Experimental Rheumatology” December 2021 in “Zenodo (CERN European Organization for Nuclear Research)” Long-COVID can cause lasting symptoms, but treatment with Erbisol drugs may help.
14 citations
,
October 1977 in “The Lancet”
49 citations
,
January 2018 in “Immunology” Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
April 2018 in “Journal of Investigative Dermatology” IL-17C is important in inflammatory skin diseases and could be a target for treatment.
9 citations
,
January 2015 in “Dermatology Online Journal” A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.